September 7, 2020
Sapere Bio selected by the NIH to participate and present at the RESI conference to advance commercial development of innovative technologies
August 25-27, 2020
NextGen Advancing Diagnostics Virtual Global Summit
Connect with us at NextGen Dx, promising in-depth insights from diagnostics leaders, regulators and reimbursement experts
August 24, 2020
Accelerated aging and senescence linked in childhood cancer survivors
New data from Smitherman and colleagues at UNC, utilizing Sapere Bio technology, demonstrates the role of p16 in chemotherapy-accelerated aging, frailty and sarcopenia
July 26, 2020
Sapere Bio expands headquarters in RTP, NC
Doubled office space at "Frontier" headquarters in Research Triangle Park, a entrepreneurial biotech hub
February 25, 2020
Enrollment opens for GUARD-AKI Validation Trial
Multi-site clinical trial of AKI-Sapere commences, supported by NIA Phase 2 SBIR funding
February 24-27, 2020
25th Annual AKI and CRRT Conference
Updated data presented at leading international conference on acute kidney injury
March 1, 2019
15th Annual Biomarkers in Heart Failure and ACS Conference
We attended the 15th Annual Biomarkers in Heart Failure and ACS meeting in La Jolla, CA.
February 26-28, 2019
24th Annual AKI and CRRT Conference
Poster presentation of new data demonstrating AKI-Sapere can stratify patients by risk AKI before either CABG or cath/PCI.
January 1, 2019
HealthSpan Dx Renamed Sapere Bio
Sapere derives from the Latin meaning "to know."
November 30, 2018
2018 Geriatric Oncology Symposium
Natalia Mitin (HealthSpan Dx CEO), Hyman Muss, Andrew Smitherman, and Kirsten Nyrop (UNC clinicians) presented on p16 biomarker applications in oncology. More info
September 23-34, 2018
Precision Medicine World Conference 2018 Duke
Natalia Mitin, HealthSpan Dx CEO, presented "Bringing Biomarkers of Aging Into the Clinic."